News

JYANT Technologies, Inc. receives notice of a Small Business Technology Transfer (STTR) R41 CA214080-01 grant, $300,000 award, from the National Institutes of Health National Cancer Institute, titled "Anti-CCL25 mAb to treat castration resistant prostate cancer". Chemoresistance and cancer drug toxicities hinder the use of many cancer drugs to treat this disease. This study demonstrates the utility of targeting the CCL25-CCR9 axis in CRPC to lower docetaxel dosage and associated chemoresistance.

Granted US #9,493,531 patent for the composition and methods of making PITPNM3, GPR30, and CCR8 protein antagonists for the treatment of cancers and inflammatory diseases.

JYANT Technologies, Inc. files an Amicus Brief, in regards to the Sequenom, Inc. v. Ariosa Diagnostics, Inc., Natera, Inc. and DNA Diagnostics Center, Inc. Our amicus brief supports the petitioner, Sequenom, Inc., by clarifying what can constitute patent-eligible inventions under the Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012) precedent and 35 U.S.C. § 101. Almost every diagnostic test relies on some natural phenomenon. However, under the Federal Circuit's reasoning, one could argue that the invention of PCR itself would not be eligible for patent protection, even though it revolutionized biotechnology. Our brief, filed by Andrews Kurth, LLP, will allow the US Supreme Court to better explain the various types of molecular diagnostic inventions that are eligible for patent protection.

Granted US #9,249,204 patent for compositions and methods of making CXCR4 protein antagonists for the treatment of cancers and inflammatory diseases.

Granted US #9,233,120 patent for preventing and treating cancers using anti-CCL25 and -CCR9 antibodies.

JYANT Technologies, Inc. receives notice of allowance from the US Patent Office for US 13/324,633 patent application titled "Anti-CCL25 and Anti-CCR9 Antibodies for the Prevention and Treatment of Cancer and Cancer Cell Migration". This invention provides methods and compositions to detect, prevent, and treat metastasis of carcinomas (e.g., prostate, breast, colorectal, ovarian cancers and other solid tumors).

Other amicus briefs are filed in support of Sequenom's petition for rehearing en banc by JYANT Technologies, Inc. JYANT contends that the panel decision "fundamentally misreads" the Court's precedent, from Funk Brothers Seed Co. v. Kalo Co., 333 U.S. 127 (1948), through Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). JYANT argues that the panel decision "threatens to undermine patent protection for a wide variety of inventions, including diagnostic tests" and "decimate the very legal protection that incentivizes the development of so many useful tools that improve the human condition." http://www.patentdocs.org/2015/09/amicus-briefs-in-support-of-sequenoms-petition-for-rehearing-en-banc-jyant-technologies-inc.html

JYANT Technologies, Inc. files Amicus Brief, along with Novartis AG, BIO, PhRMA and others, seeking en banc rehearing of Ariosa v. Sequenom. In short, the brief sites Diamond v. Diehr ...the Supreme Court explanation that "a new combination of steps in a process may be patentable even though all the constituents of the combination were well known and in common use before the combination was made."

JYANT Technologies, Inc. receives notice of a Small Business Technology Transfer (STTR) R41 MD010320-01 grant, $315,320 award, from the National Institutes of Health National Institute on Minority Health and Health Disparities, titled "Anti-CXCL13 mAb to Mitigate Prostate Cancer Health Disparities". To date, there is no cure for metastatic hormone refractory prostate cancer (HRPC). Chemoresistance, toxicities, and variable response rates hinder the use of many cancer drugs to treat this disease. This study demonstrates the utility of targeting the CXCL13-CXCR5 axis in HRPC, especially prevalent in African Americans with this disease.

Granted US #8,987,210 patent for compositions and methods of making CCR9 protein antagonists for the treatment of cancers and inflammatory diseases.

JYANT Technologies, Inc. receives notice of a Small Business Technology Transfer (STTR) R41 CA183399-01A1 grant, $225,000 award, from the National Institutes of Health National Cancer Institute, titled "Novel adjuvant therapy for triple negative breast cancer". The leptin/leptin receptor complex has several oncogenic effects in triple negative breast cancer (TNBC), particularly in obese individuals. The proposed project will shows the utility of a novel adjuvant therapeutic of PEG-wLPrA2 on TNBC.

Granted US #8,962,030 patent for treating cancers using planetary ball milled nanoparticle compositions of controllable size and surface characteristics containing cytotoxic drugs.

Granted US #8,796,422 patent for compositions and methods of making CCR2 and CCR4 protein antagonists for the treatment of cancers and inflammatory diseases.

Granted US #8,658,377 patent for early detection of ovarian cancer by monitoring CCL25, CCR9 and other biomarkers found in serum, saliva and urine.

Granted US #8,580,261 patent for preventing and treating inflammatory diseases using anti-CCL25 antibodies.

Granted US #8,568,784 patent for planetary ball milled nanoparticle compositions of controllable size and surface characteristics for the delivery of biologically active agents.

Granted US #8,563,476 patent for detecting the course of inflammatory diseases by monitoring CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5 and other biomarkers.

Granted US #8,541,564 patent for compositions and methods of making CXCR3 and CXCR7 protein antagonists for the treatment of cancers and inflammatory diseases.

JYANT Technologies, Inc. receives notice of a Small Business Innovative Research (SBIR) R43 DK096857-01A1 grant, $294,331 award, from the National Institutes of Health National Institute of Diabetes, Digestive and Kidney Diseases, titled "Treatment of Colitis using a Novel CXCR4 Biologic Antagonist". This proposal uses a novel chemokine receptor, CXCR3 (upregulated during Inflammatory Bowel Disease; IBD), protein antagonist to mitigate mouse colitis, which are similar to human IBD.

Granted US #8,512,701 patent for treating primary and advanced metastatic cancers using anti-CXCL13 and anti-CXCR5 antibodies.

Granted US #8,318,170 patent for preventing and treating inflammatory diseases using anti-CXCL9 and anti-CXCL11 antibodies.

Granted US #8,231,907 patent for nano-compounding methods and compositions of controllable size and surface characteristics, using planetary ball milling.

Granted US #8,097,250 patent for treating melanoma using anti-CXCL13 and anti-CXCR5 antibodies.

Granted US #7,964,194 patent for detecting and treating inflammatory diseases using anti-CXCL10 antibodies.

Granted US #7,919,083 patent for treating melanoma using anti-CCL25 antibodies.